News & Updates

Dabrafenib plus trametinib boasts high pathological response for stage III melanoma
Dabrafenib plus trametinib boasts high pathological response for stage III melanoma
12 Aug 2024
Cabozantinib offers survival benefits to ICI-treated HCC patients
Cabozantinib offers survival benefits to ICI-treated HCC patients
11 Aug 2024